OM3E Stock Overview
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.50 |
| 52 Week High | US$6.20 |
| 52 Week Low | US$4.95 |
| Beta | 0 |
| 1 Month Change | -6.11% |
| 3 Month Change | -6.43% |
| 1 Year Change | -0.15% |
| 3 Year Change | -10.08% |
| 5 Year Change | 27.66% |
| Change since IPO | 31.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| OM3E | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | -1.0% | -0.8% | -2.0% |
| 1Y | -0.1% | 17.8% | -0.3% |
Return vs Industry: OM3E underperformed the German Capital Markets industry which returned 17.8% over the past year.
Return vs Market: OM3E matched the German Market which returned -0.3% over the past year.
Price Volatility
| OM3E volatility | |
|---|---|
| OM3E Average Weekly Movement | 4.9% |
| Capital Markets Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OM3E has not had significant price volatility in the past 3 months.
Volatility Over Time: OM3E's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | n/a | www.ishares.com/uk/individual/en/products/291450/ |
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States.
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF Fundamentals Summary
| OM3E fundamental statistics | |
|---|---|
| Market cap | €408.78m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs OM3E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OM3E income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did OM3E perform over the long term?
See historical performance and comparison